Literature DB >> 17434380

Raltegravir: a new antiretroviral class for salvage therapy.

Pedro Cahn1, Omar Sued2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17434380     DOI： 10.1016/S0140-6736(07)60571-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

2.  Computational design of a full-length model of HIV-1 integrase: modeling of new inhibitors and comparison of their calculated binding energies with those previously studied.

Authors:  Selami Ercan; Necmettin Pirinccioglu
Journal:  J Mol Model       Date:  2013-08-02       Impact factor: 1.810

3.  Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.

Authors:  Shintaro Suzuki; Kasthuraiah Maddali; Chie Hashimoto; Emiko Urano; Nami Ohashi; Tomohiro Tanaka; Taro Ozaki; Hiroshi Arai; Hiroshi Tsutsumi; Tetsuo Narumi; Wataru Nomura; Naoki Yamamoto; Yves Pommier; Jun A Komano; Hirokazu Tamamura
Journal:  Bioorg Med Chem       Date:  2010-07-25       Impact factor: 3.641

4.  Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.

Authors:  Carole L Wallis; Raquel V Viana; Shanmugam Saravanan; Carlos Silva de Jesus; Clement Zeh; Elias K Halvas; John W Mellors
Journal:  J Virol Methods       Date:  2016-12-16       Impact factor: 2.014

Review 5.  Adolescents and HIV: prevention and clinical care.

Authors:  Hans M L Spiegel; Donna C Futterman
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

6.  The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Authors:  Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark R Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

7.  Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.

Authors:  Andrea Low; Nicole Prada; Michael Topper; Florin Vaida; Delivette Castor; Hiroshi Mohri; Daria Hazuda; Mark Muesing; Martin Markowitz
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

8.  Cell-permeable stapled peptides based on HIV-1 integrase inhibitors derived from HIV-1 gene products.

Authors:  Wataru Nomura; Haruo Aikawa; Nami Ohashi; Emiko Urano; Mathieu Métifiot; Masayuki Fujino; Kasthuraiah Maddali; Taro Ozaki; Ami Nozue; Tetsuo Narumi; Chie Hashimoto; Tomohiro Tanaka; Yves Pommier; Naoki Yamamoto; Jun A Komano; Tsutomu Murakami; Hirokazu Tamamura
Journal:  ACS Chem Biol       Date:  2013-08-15       Impact factor: 5.100

Review 9.  Recent progress in antiretrovirals--lessons from resistance.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Drug Discov Today       Date:  2008-04-18       Impact factor: 7.851

10.  Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Authors:  Olivia Goethals; Reginald Clayton; Marcia Van Ginderen; Inge Vereycken; Elisabeth Wagemans; Peggy Geluykens; Koen Dockx; Rudy Strijbos; Veerle Smits; Ann Vos; Geert Meersseman; Dirk Jochmans; Kurt Vermeire; Dominique Schols; Sabine Hallenberger; Kurt Hertogs
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.